Skip to main content
. 2022 Sep 8;14:259–280. doi: 10.2147/BCTT.S380754

Figure 6.

Figure 6

Survival curves of DFS (A) and OS (B) for the HER2-negative, Luminal B subgroup receiving Herceptin, the Luminal B subgroup that did not receive Herceptin, the HER2-enriched subgroup that received Herceptin, and the HER2-enriched subgroup that did not receive Herceptin, producing subtype 5 using the Kaplan–Meier method.